Why is Wuhan Easy Diagnosis Biomedicine Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -30.21% and Operating profit at -172.67% over the last 5 years
2
The company has declared Negative results for the last 3 consecutive quarters
- NET SALES(HY) At CNY 108.94 MM has Grown at -43.96%
- NET PROFIT(HY) At CNY -32.4 MM has Grown at -189.74%
- ROCE(HY) Lowest at -0.23%
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -27.10%, its profits have fallen by -980.5%
- At the current price, the company has a high dividend yield of 11.8
4
Below par performance in long term as well as near term
- Along with generating -27.10% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Wuhan Easy Diagnosis Biomedicine Co., Ltd. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Wuhan Easy Diagnosis Biomedicine Co., Ltd.
-18.51%
-0.71
27.97%
China Shanghai Composite
3.23%
1.20
14.07%
Quality key factors
Factor
Value
Sales Growth (5y)
-30.21%
EBIT Growth (5y)
-172.67%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.55
Sales to Capital Employed (avg)
0.07
Tax Ratio
20.49%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
54.94%
ROE (avg)
32.63%
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.60
EV to EBIT
3.27
EV to EBITDA
4.09
EV to Capital Employed
-0.40
EV to Sales
-2.39
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-1.28%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
No Trend
Technical Movement
3What is working for the Company
DEBTORS TURNOVER RATIO(HY)
Highest at 0.41 times
CASH AND EQV(HY)
Highest at CNY 7,733.83 MM
-26What is not working for the Company
NET SALES(9M)
At CNY 179.7 MM has Grown at -31.86%
INTEREST(HY)
At CNY 0.27 MM has Grown at 349.13%
PRE-TAX PROFIT(Q)
At CNY -32.51 MM has Fallen at -105.78%
ROCE(HY)
Lowest at -0.93%
RAW MATERIAL COST(Y)
Grown by 40.14% (YoY
NET PROFIT(Q)
Lowest at CNY -36.36 MM
Here's what is working for Wuhan Easy Diagnosis Biomedicine Co., Ltd.
Debtors Turnover Ratio
Highest at 0.41 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Cash and Eqv
Highest at CNY 7,733.83 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Wuhan Easy Diagnosis Biomedicine Co., Ltd.
Interest
At CNY 0.27 MM has Grown at 349.13%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CNY MM)
Net Sales
At CNY 179.7 MM has Grown at -31.86%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (CNY MM)
Pre-Tax Profit
At CNY -32.51 MM has Fallen at -105.78%
over average net sales of the previous four periods of CNY -15.8 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (CNY MM)
Net Profit
At CNY -36.36 MM has Fallen at -927.73%
over average net sales of the previous four periods of CNY -3.54 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (CNY MM)
Net Profit
Lowest at CNY -36.36 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (CNY MM)
Raw Material Cost
Grown by 40.14% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading






